# First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/first-line-durvalumab-plus-platinum-etoposide-versus-platinum-etoposide-for/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Longfeng Zhang,Yongfu Hang,Maobai Liu,Na Li,Hongfu Cai |
| Citations | 36 |
| DOI | 10.3389/fonc.2020.602185 |
| Fields | Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://www.frontiersin.org/articles/10.3389/fonc.2020.602185/pdf |
| OpenAlex ID | https://openalex.org/W3108036228 |
| PMID | 33344252 |
| Type | article |
| Year | 2020 |

## Paper authors

- [Longfeng Zhang](https://scholariq.org/researchers/longfeng-zhang/)

## Paper journal

- [Frontiers in Oncology](https://scholariq.org/journals/frontiers-in-oncology/)

## Paper primary topic

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Paper topics

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.